Filtered By:
Drug: Activase

This page shows you your search results in order of date. This is page number 19.

Order by Relevance | Date

Total 1186 results found since Jan 2013.

Determinants for a low dose of alteplase and its relationship to a lower intracerebral bleeding risk in acute ischemic stroke
Conclusions: Patients with increasing age, a higher baseline systolic blood pressure, and previous ischemic stroke were at a higher odd of receiving a low-dose of alteplase. The low-dose was associated with a lower risk of developing symptomatic intracranial hemorrhage.PMID:36313231 | PMC:PMC9608043 | DOI:10.7150/ijms.76105
Source: International Journal of Medical Sciences - October 31, 2022 Category: Biomedical Science Authors: Jie Chen Hangfeng Li Hanhan Lei Shuangfang Fang Qilin Yuan Yangui Chen Dongping Chen Ronghua Chen Yixian Zhang Jin Wei Guangliang Chen Zhiting Chen Nan Liu Hou-Wei Du Source Type: research

In acute ischemic stroke, thrombectomy was not noninferior to alteplase + thrombectomy for 90-d functional independence
Ann Intern Med. 2022 Nov 1. doi: 10.7326/J22-0088. Online ahead of print.ABSTRACTFischer U, Kaesmacher J, Strbian D, et al. Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke: an open-label, blinded-outcome, randomised non-inferiority trial. Lancet. 2022;400:104-15. 35810756.PMID:36315954 | DOI:10.7326/J22-0088
Source: Annals of Internal Medicine - October 31, 2022 Category: Internal Medicine Authors: Anthony A Donato Vaibhav Goswami Source Type: research

In acute ischemic stroke, early IV tenecteplase was noninferior to alteplase for excellent functional outcome
Ann Intern Med. 2022 Nov 1. doi: 10.7326/J22-0090. Online ahead of print.ABSTRACTMenon BK, Buck BH, Singh N, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet. 2022;400:161-9. 35779553.PMID:36315948 | DOI:10.7326/J22-0090
Source: Annals of Internal Medicine - October 31, 2022 Category: Internal Medicine Authors: Emma Ferguson Eddy Lang Source Type: research

Determinants for a low dose of alteplase and its relationship to a lower intracerebral bleeding risk in acute ischemic stroke
Conclusions: Patients with increasing age, a higher baseline systolic blood pressure, and previous ischemic stroke were at a higher odd of receiving a low-dose of alteplase. The low-dose was associated with a lower risk of developing symptomatic intracranial hemorrhage.PMID:36313231 | PMC:PMC9608043 | DOI:10.7150/ijms.76105
Source: International Journal of Medical Sciences - October 31, 2022 Category: Biomedical Science Authors: Jie Chen Hangfeng Li Hanhan Lei Shuangfang Fang Qilin Yuan Yangui Chen Dongping Chen Ronghua Chen Yixian Zhang Jin Wei Guangliang Chen Zhiting Chen Nan Liu Hou-Wei Du Source Type: research

In acute ischemic stroke, thrombectomy was not noninferior to alteplase + thrombectomy for 90-d functional independence
Ann Intern Med. 2022 Nov 1. doi: 10.7326/J22-0088. Online ahead of print.ABSTRACTFischer U, Kaesmacher J, Strbian D, et al. Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke: an open-label, blinded-outcome, randomised non-inferiority trial. Lancet. 2022;400:104-15. 35810756.PMID:36315954 | DOI:10.7326/J22-0088
Source: Annals of Internal Medicine - October 31, 2022 Category: Internal Medicine Authors: Anthony A Donato Vaibhav Goswami Source Type: research

In acute ischemic stroke, early IV tenecteplase was noninferior to alteplase for excellent functional outcome
Ann Intern Med. 2022 Nov 1. doi: 10.7326/J22-0090. Online ahead of print.ABSTRACTMenon BK, Buck BH, Singh N, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet. 2022;400:161-9. 35779553.PMID:36315948 | DOI:10.7326/J22-0090
Source: Annals of Internal Medicine - October 31, 2022 Category: Internal Medicine Authors: Emma Ferguson Eddy Lang Source Type: research

Determinants for a low dose of alteplase and its relationship to a lower intracerebral bleeding risk in acute ischemic stroke
Conclusions: Patients with increasing age, a higher baseline systolic blood pressure, and previous ischemic stroke were at a higher odd of receiving a low-dose of alteplase. The low-dose was associated with a lower risk of developing symptomatic intracranial hemorrhage.PMID:36313231 | PMC:PMC9608043 | DOI:10.7150/ijms.76105
Source: International Journal of Medical Sciences - October 31, 2022 Category: Biomedical Science Authors: Jie Chen Hangfeng Li Hanhan Lei Shuangfang Fang Qilin Yuan Yangui Chen Dongping Chen Ronghua Chen Yixian Zhang Jin Wei Guangliang Chen Zhiting Chen Nan Liu Hou-Wei Du Source Type: research

In acute ischemic stroke, thrombectomy was not noninferior to alteplase + thrombectomy for 90-d functional independence
Ann Intern Med. 2022 Nov 1. doi: 10.7326/J22-0088. Online ahead of print.ABSTRACTFischer U, Kaesmacher J, Strbian D, et al. Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke: an open-label, blinded-outcome, randomised non-inferiority trial. Lancet. 2022;400:104-15. 35810756.PMID:36315954 | DOI:10.7326/J22-0088
Source: Annals of Internal Medicine - October 31, 2022 Category: Internal Medicine Authors: Anthony A Donato Vaibhav Goswami Source Type: research

In acute ischemic stroke, early IV tenecteplase was noninferior to alteplase for excellent functional outcome
Ann Intern Med. 2022 Nov 1. doi: 10.7326/J22-0090. Online ahead of print.ABSTRACTMenon BK, Buck BH, Singh N, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet. 2022;400:161-9. 35779553.PMID:36315948 | DOI:10.7326/J22-0090
Source: Annals of Internal Medicine - October 31, 2022 Category: Internal Medicine Authors: Emma Ferguson Eddy Lang Source Type: research

Determinants for a low dose of alteplase and its relationship to a lower intracerebral bleeding risk in acute ischemic stroke
Conclusions: Patients with increasing age, a higher baseline systolic blood pressure, and previous ischemic stroke were at a higher odd of receiving a low-dose of alteplase. The low-dose was associated with a lower risk of developing symptomatic intracranial hemorrhage.PMID:36313231 | PMC:PMC9608043 | DOI:10.7150/ijms.76105
Source: International Journal of Medical Sciences - October 31, 2022 Category: Biomedical Science Authors: Jie Chen Hangfeng Li Hanhan Lei Shuangfang Fang Qilin Yuan Yangui Chen Dongping Chen Ronghua Chen Yixian Zhang Jin Wei Guangliang Chen Zhiting Chen Nan Liu Hou-Wei Du Source Type: research